PDF | On Jan 1, , E.M. Ginzler and others published Aspreva Lupus Management Study (ALMS): Maintenance Results. [abstract]. *Members of the Aspreva Lupus Manage- ment Study (ALMS) Group are listed in the Supplementary Appendix, available at The study group underwent repeat randomization in a ratio. A total of patients were randomly assigned to maintenance treatment ( to a renal response to treatment and in preventing relapse in patients with lupus (Funded by Vifor Pharma [formerly Aspreva]; ALMS number, NCT).
|Published (Last):||14 February 2007|
|PDF File Size:||11.91 Mb|
|ePub File Size:||13.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
J Am Soc Nephrol. Efficacy The primary efficacy end point was achieved lupu Moreover, although the subgroups are prespecified, the study is not specifically powered to detect differences and the somewhat increased death rate and difference in adverse event profile compared to other studies is not explained. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. During the study, any drugs affecting the angiotensin system were taken at stable dosage.
ALMS – Wiki Journal Club
In the MMF group, 35 It has been reported that black and Hispanic patients are at an increased risk for aggressive disease. The h urine collections were obtained at baseline and every 4 wk thereafter until completion of the wk induction phase.
For both treatments, the most common AEs were infections and gastrointestinal disorders, occurring in approximately two thirds of patients. The response rates were similar between patients with renal biopsy class III or IV and those with renal biopsy class V, irrespective of treatment.
A new prediction equation. The corresponding mean number of doses of IVC was stduy. Published online ahead of print. Bernardo Houssay, San Janagement, Argentina.
Overall, the mean dosage of prednisone did not differ between groups For patients in the IVC group and for patients in each of the self-reported racial groups, the median number of doses was 6. Patients who were aged 12 to 75 yr and had a diagnosis of SLE by American College of Rheumatology criteria 33 were enrolled between July 27,and October 6, IVC was given in monthly pulses of 0.
Of patients screened, were randomly assigned Figure 1. N Engl J Med In the sensitivity analysis, the number of patients achieving the primary efficacy end point was not statistically significantly different between treatment groups, irrespective of adjustment for covariates.
Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.
Navigation menu Personal tools Create account Log in. The most commonly reported AEs are shown in Table 4. Appel GB, et al.
Pulse intravenous corticosteroids were prohibited within 2 wk before first randomization and throughout the study.
The numbers of patients receiving concomitant medications were mostly similar between treatment groups. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. A systematic review and meta-analysis. Although the rationale for MMF included decreased gonadal toxicity, this outcome was not reported asprsva this study since such toxicity was not expected to be observed at 24 weeks.
Demographics and baseline disease characteristics were similar between the treatment groups Table 1.
Time since diagnosis of lupus nephritis yr; median [range] k. Ann Intern Med Update on the treatment of lupus nephritis.
Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: